Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06876662 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

StatusRecruiting
PhasePhase 4
Started2025-05-20
View on ClinicalTrials.gov ↗
Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned study intervention or continue their follow-up visits by transitioning to this study. This study will evaluate the long-term safety and efficacy of pirtobrutinib.

Amendment record

Amended 11 times since 2025-03-13; most recent filed 2026-02-27. Every amendment is listed below.

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-30.

2026-02-27
Amendment Study Status, Contacts/Locations v11
2026-01-19
Amendment Study Status v10
2025-12-03
Amendment Study Status, Contacts/Locations v9
2025-11-19
Amendment Study Status, Contacts/Locations v8
2025-10-10
Amendment Study Status, Contacts/Locations v7
2025-09-25
Amendment Study Status, Oversight, Outcome Measures, Contacts/Locations v6
2025-08-22
Amendment Study Identification, Study Status, Oversight, Outcome Measures, Eligibility, Contacts/Locations v5
2025-07-18
Amendment Study Status, Contacts/Locations v4
2025-06-18
Amendment Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v3
2025-05-27
Amendment Study Status, Contacts/Locations v2
2025-04-18
Amendment Study Status, Contacts/Locations v1
2025-03-13
Original filing
Trial Details
NCT Number NCT06876662
Lead Sponsor Eli Lilly and Company
Conditions Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
Enrollment 279 participants
Start Date 2025-05-20
Primary Completion 2030-05 (estimated)
Study Completion 2032-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-02